Retatrutide for Perimenopause Weight Changes: Evidence and Considerations

Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.

Study eligibility limits the conclusion

The phase 2 obesity study enrolled 338 adults with obesity, or overweight with a weight-related condition. Enrollment rules and exclusions determine which people its findings describe. The overall result cannot establish the benefit-risk balance for every age group, diagnosis, BMI category, occupation or demographic population.

For the population or condition named in this article, check whether it was actually studied and whether the relevant outcome was prespecified. A biological connection or improvement in a laboratory marker does not prove treatment of a separate disease. A subgroup observation can also be too small or exploratory to support a clinical conclusion.

The sources here do not establish retatrutide as an approved treatment for this population or condition. Eligibility for research is determined by the individual protocol, not by a website BMI calculator or a telehealth assessment. No personalized suitability or adjustment of other treatment can be inferred from this article.

How to evaluate a claim about this topic

The question "Retatrutide for Perimenopause Weight Changes: Evidence and Considerations" needs evidence that matches the actual claim. Identify the named study, the population enrolled and the outcome measured. Check whether the result was prespecified, whether there was a relevant comparator, and whether the report includes harms as well as benefits. The studies linked below provide context; they do not establish every claim implied by this question.

Sources

• FDA: unapproved GLP-1 drugs
• Phase 2 obesity trial (NEJM, 2023)
• Phase 2 study registration (NCT04881760)